Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomized, controlled, phase 2b trial.

• 2023.01.26 ｜ 抄読会論文